Z-VAD-FMK

Z-VAD-FMK

To Order Now: info@anbioq.org

Z-VAD-FMK
HY-16658B 10mg
EUR 655

Z-VAD-FMK
abx076838-1mg 1 mg
EUR 342

Z-VAD-FMK
A1902-1 1 mg
EUR 113
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2.

Z-VAD-FMK
A1902-10 10 mg
EUR 340
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2.

Z-VAD-FMK
A1902-25 25 mg
EUR 514
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2.

Z-VAD-FMK
A1902-5 5 mg
EUR 224
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2.

Z-VAD-FMK
A1902-5.1 10 mM (in 1mL DMSO)
EUR 224
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2.

Z-VAD(OMe)-FMK
HY-16658 10mg
EUR 394

Z-VAD-FMK, cell permeable
GL1523-1MG 1 mg
EUR 275

Z-VAD-FMK, cell permeable
GL1523-5MG 5 mg
EUR 792

Caspase-Family Inhibitor Z-VAD-FMK
1010-100
EUR 196

Caspase-Family Inhibitor Z-VAD-FMK
1010-20C
EUR 196

SRB-VAD-FMK [Sulforhodamine B-VAD-FMK]
13472 25 Tests
EUR 132

FITC-VAD-FMK
9497-100
EUR 359

Biotin-VAD-FMK
1123-20C
EUR 327

FAM-VAD-FMK
13470 25 Tests
EUR 132

TF4-VAD-FMK
13471 25 Tests
EUR 132

Biotin-VAD-FMK
HY-100894 1mg
EUR 1014

Z-VAD-FMK (Pan-specific caspase inhibitor)
SIH-557-1MG 1 mg
EUR 193
Description: The substance Z-VAD-FMK is a pan-specific caspase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is lyophilized solid or wax which is May be dissolved in DMSO (10 mg/ml).

mFluor™ 450-VAD-FMK
13475 25 Tests
EUR 132

mFluor™ 510-VAD-FMK
13476 25 Tests
EUR 132

Z-YVAD-FMK
1141-1
EUR 338

Z-YVAD-FMK
1141-5
EUR 805

Z-VDVAD-FMK
1142-1
EUR 305

Z-VDVAD-FMK
1142-5
EUR 805

Z-DEVD-FMK
1143-1
EUR 316

Z-DEVD-FMK
1143-5
EUR 805

Z-LEVD-FMK
1144-1
EUR 316

Z-LEVD-FMK
1144-5
EUR 805

Z-VEID-FMK
1146-1
EUR 305

Z-VEID-FMK
1146-5
EUR 805

Z-IETD-FMK
1148-1
EUR 327

Z-IETD-FMK
1148-5
EUR 784

Z-LEHD-FMK
1149-1
EUR 316

Z-LEHD-FMK
1149-5
EUR 767

Z-ATAD-FMK
1152-1
EUR 349

Z-ATAD-FMK
1152-5
EUR 914

Z-FA-FMK
1986-1
EUR 147

Z-FA-FMK
1986-5
EUR 370

Z-AEVD-FMK
B1162-1
EUR 338

Z-VRPR-FMK
B1238-1000
EUR 914

Z-VRPR-FMK
B1238-250
EUR 338

Z-IETD-FMK
HY-101297 5mg
EUR 463

Z-DEVD-FMK
HY-12466 10mg
EUR 393

Z-VRPR-FMK
GL3755-1MG 1 mg
EUR 585

Z-VRPR-FMK
GL3755-500UG 500 ug
EUR 355

Z-DEVD-FMK
A1920-1 1 mg
EUR 113
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-10 10 mg
EUR 340
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-25 25 mg
EUR 514
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-5 5 mg
EUR 224
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-5.1 10 mM (in 1mL DMSO)
EUR 293
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-S Evaluation Sample
EUR 81
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DQMD-FMK
A1921-1 1 mg
EUR 113
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-10 10 mg
EUR 340
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-25 25 mg
EUR 514
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-5 5 mg
EUR 224
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-5.1 10 mM (in 1mL DMSO)
EUR 432
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-S Evaluation Sample
EUR 81
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-VDVAD-FMK
A1922-1 1 mg
EUR 177
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK
A1922-10 10 mg
EUR 630
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK
A1922-25 25 mg
EUR 978
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK
A1922-5 5 mg
EUR 398
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK
A1922-S Evaluation Sample
EUR 81
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VEID-FMK
A1923-1 1 mg
EUR 177
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK
A1923-10 10 mg
EUR 630
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK
A1923-25 25 mg
EUR 978
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK
A1923-5 5 mg
EUR 398
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK
A1923-S Evaluation Sample
EUR 81
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-WEHD-FMK
A1924-1 1 mg
EUR 113
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-WEHD-FMK
A1924-10 10 mg
EUR 340
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-WEHD-FMK
A1924-25 25 mg
EUR 514
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-VAD-FMK